Erika Hamilton Presented VERITAC-2 Results on Vepdegestrant at ASCO 2025
Erika Hamilton, Medical Oncologist and the Director of Breast Cancer Program at the Sarah Cannon Research Institute, posted on LinkedIn:
“Today marks a defining moment in the advancement of targeted therapies for breast cancer.
This afternoon at ASCO 2025, I will be presenting findings from the VERITAC-2 study evaluating vepdegestrant, a PROTAC estrogen receptor degrader, in patients with ER+/HER2-metastatic breast cancer, the most common subtype accounting for ~70% of all breast cancer cases. The results, now published in the NEJM Group, show a 43% reduction in risk of progression or death in patients with ESR1 mutations, compared to intramuscular SERD therapy.
This finding highlights the need to better understand patient subgroups and resistance mechanisms. By offering unique approaches like PROTACs when standard protocols fall short, patients can ultimately access more meaningful choices.
You can read the full paper here.”
Title: Vepdegestrant, a PROTAC Estrogen Receptor Degrader, in Advanced Breast Cancer
Journal: NEJM
Authors: Mario Campone, Michelino De Laurentiis, Komal Jhaveri, Xichun Hu, Sylvain Ladoire, Anne Patsouris, Claudio Zamagni, Jiuwei Cui, Marina Cazzaniga, Timucin Cil, Katarzyna J. Jerzak, Christian Fuentes, Tetsuhiro Yoshinami, Alvaro Rodriguez-Lescure, Ahmet Sezer, Andrea Fontana, Valentina Guarneri, Andrea Molckovsky, Marie-Ange Mouret-Reynier, Umut Demirci, Yongqiang Zhang, Olga Valota, Dongrui R Lu, Marcella Martignoni, Janaki Parameswaran, Xin Zhi, Erika P. Hamilton
More posts featuring Erika Hamilton on OncoDaily.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023